1. Tinostamustine (EDO-S101)is an AK-DACi (a first-in-class alkylating deacetylase inhibiting molecule) that, in preclinical studies, has been shown to improve access to the DNA strands within cancer cells, break them and counteract damage repair.1-3 Preclinical studies suggest that these complementary and simultaneous modes of action have the potential to overcome resistance.3,4
1.López-Iglesias AA. The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies. Blood 2014; 124: (21).
2.López-Iglesias AA. preclinical antimyeloma activity of EDO-S101 (bendamustine-vorinostat fusion molecule) through DNA-damaging and HDACi effects. 15th International Myeloma Workshop. 23−26 September 2015. Rome, Italy.
3.Di Filippi R, et al. The First-In-Class Alkylating Histone Deacetylase Inhibitor (HDACi) Fusion Molecule EDO-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine Resistant Clones. 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), 6 December 2015.
4.Yan S, Xu K, Lin J, et al. Synergistic inhibition of tumor growth and overcoming chemo-resistance by simultaneously targeting key components in DNA damage/repair, epigenetic, and putative cancer stem cell signaling pathways using novel dual-functional DNA-alkylating/HDAC inhibitor and tumor suppressor gene nanoparticles in lung cancer. Cancer Research 2012;72( Suppl 1): Abstract 2741.
Mundipharma EDO GmbH
St. Alban-Rheinweg 74
Phone: +41 61 205 1470
Dr. Mehrling was appointed Managing Director of EDO GmbH, Basel, in January 2013 and became CEO in 2016. He brings extensive experience with more than 17 years in the industry to this role. During his career, he has held various senior positions in different companies across almost all functions in drug development and commercialisation. Most recently, he held the position of International Director Oncology Strategy (2011–2013). From 2004 to 2011 he served as European Director Oncology at Mundipharma International Ltd. During his tenure the oncology business of the European Mundipharma network of independent associated companies was set up and two major products were launched in Europe, DepoCyte® and Levact® (Ribomustin®, Treanda®). He joined Mundipharma in 2000 as Head of Business Development. Prior to Mundipharma, he was Senior Vice President of the global CRO Medical Affairs at Staticon International, and prior to this he acted as Medical Leader at Takeda European R&D center. Dr. Mehrling is a certified Pharmacist with a Ph.D. in pharmacology and a certified Physician trained in haemato-oncology. He obtained his Ph.D. from Frankfurt University following work on developing a new 5-HT3 antagonist to treat nausea and vomiting and developed a particular interest in mechanisms of multi-drug resistance into chemotherapy. Dr. Mehring earned his M.D. degree through his work in the Department of Internal medicine at Frankfurt University (Hemato-oncology and Cardiology) where he worked for several years before starting his career in the pharmaceutical industry.
Dr. Guggi served in different commercial management positions within the Mundipharma network of independent associated companies between 2004 and 2013. His latest responsibility was leading the company’s marketing and sales department in Austria, while being also responsible for business development and market access. In his previous positions he developed and led the Oncology Business Unit in Austria and Central Eastern Europe (CEE), successfully launching DepoCyte® and Levact® and setting a benchmark within Europe. He also coordinated post-approval clinical development for the oncology brands in Austria and CEE. Prior to that he served as European Product Manager Oncology at Mundipharma International. Overall, Dr. Guggi gained 10 years of extensive experience and in depth knowledge of the haemato-oncology field and was member of the Oncology Steering Committee of Mundipharma.
Dr. Guggi earned his Ph.D. in Pharmaceutical Technology and Biopharmacy at the University of Vienna and has several scientific publications in the field of oral drug delivery and bioavailability.
Dr. Soltis has worked in the field of cancer drug discovery for nearly 30 years directing projects focused on traditional small molecule drugs as well as a range of biological agents including proteins, DNA and siRNA. He began his career in pharmaceutical drug discovery at Sandoz/Novartis where, early in his career, he helped establish and direct a core molecular biology group before joining the Oncology Department. In the Oncology Department, he was promoted to Program Team Leader and managed drug discovery projects in collaboration with faculty members at the Dana Farber Cancer Institute targeting signal transduction pathways critical to cancer cell proliferation and survival. In 1999, Dr. Soltis joined Purdue Pharma, to establish a Molecular Biology group and help set up a cancer immunotherapy programme. In 2001, he was promoted to Senior Director of the Cancer Immunotherapy Department and in the following 3 years led the discovery of two antibodies for the treatment of cancer that were advanced into development. In 2007, Dr. Soltis joined a small biotechnology company, Nucleonics, to develop an oncology programme using the company’s novel expressed interfering RNA (eiRNA) technology to treat cancer. Significant progress was made in identifying an agent for the treatment of prostate cancer prior to the closure of the company at the end of 2008. Dr. Soltis received his Ph.D. in chemistry from the University of Illinois, Urbana-Champaign.
Dr. Evan Vosburgh is Executive Director of the Raymond and Beverly Sackler Foundation based in New York City and Stamford, Connecticut. The private Foundation funds academic programmes broadly in the sciences, as well as operating a laboratory focused on neuroendocrine cancer biology. He is a board certified Haematologist and Medical Oncologist who served on the faculty of the Boston University School of Medicine for 10 years where he combined clinical care, teaching, administrative oversight of clinical research programmes in cancer clinical trials, haemophilia, and systemic amyloidosis, including autologous stem cell therapy. Dr. Vosburgh maintains teaching and clinical responsibilities as a Clinical Associate Professor at the Yale School of Medicine and West Haven Veterans Hospital. He lives in New York City with his wife Betsy Myers, Ph.D. who directs medical research at the Doris Duke Charitable Foundation. His daughter Jessica is a graduate of Yale Law School and a Public Interest Lawyer at NDLON, and son Brendan is a graduate of Colorado College and a 1st Lieutenant in the US Army. Dr. Vosburgh received a BS in Zoology from Duke University and M.D. from Albany Medical College, and completed his haematology and oncology fellowship training at the Boston City Hospital (now Boston Medical Center).
Paul joined the Mundipharma associated companies in 2011, bringing 20 years of experience in biopharmaceuticals and in corporate and business development, including early technology acquisitions, academic collaborations, in- and out-licensing, joint ventures, corporate start-up, corporate acquisitions and other strategic alliance development. Over that period, he completed or directed over $3 billion in business development transactions.
Prior to joining Mundipharma, Paul served as Senior Vice President and Chief Business Officer at AVI BioPharma (now Serepta Therapeutics), a technology-innovating developer of RNA-based therapeutics. Previously, he served as Vice President, Global Licensing and Strategic Alliances for Schering-Plough, and earlier as Head of Global Marketing for the company’s Allergy franchise. Paul began his biopharmaceutical career at Merck & Company, where he held positions in sales, new product planning and worldwide marketing.
Paul holds an AB with honors from Brown University and an MBA from Columbia Business School.
Antony is the Managing Director for Europe at MINT. He has worked in the pharmaceutical industry since 1991, gaining experience from a wide range of territories including Asia, the US and the European Union. He worked for an equally diverse range of companies, including Schering Plough, MSD, BMS and Novartis before joining the Mundipharma network over 10 years ago as General Manager at Napp. Antony’s wide-ranging industry experience includes swine and poultry marketing, global marketing, new product planning and business development. Unexpectedly, before entering marketing Antony studied terrorism before it became quite so fashionable amongst academics.
Kinesis Pharma is an international operating consultancy and contract research organization with headquarters in Breda (1997), the Netherlands and a regional office in Singapore (2010). Kinesis leverages the expertise and experience of its highly-skilled, multi-disciplinary workforce to accelerate development of medicinal products, either small molecules or biologics, herbal medicines or nutraceuticals. This unique concentration of multidisciplinary experts – combined with a direct and pragmatic approach – presents sponsors with flexible service options to cope with fluctuations in business requirements.
Makara Health is an independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is a creative launch campaign for a new or re-launched brand, a training or education programme, market preparedness, or a PR programme to impact awareness, we fuse robust psychological theory with inspirational ideas to create exciting programmes that deliver real results.
EDO GmbH is part of the Mundipharma network of independent associated companies, which consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and rheumatoid arthritis. They are also committed to independent thinking and ground-breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting-edge treatments to meet the most pressing needs of healthcare professionals and patients.
Northlake International LLC is a venture-backed, early stage drug development company, focusing on the acquisition, development and commercialisation of novel Dual Functional Cytotoxic Targeted Therapy (DCTT) in a worldwide market, to address the unmet need for improved therapy for cancer patients.
Purdue Pharma L.P. is a privately held pharmaceutical company committed to improving patients’ lives by providing safe and effective therapies along with educational tools that support their proper use. Purdue Pharma is a member company of a network of independent associated companies which are engaged in the research, development, production, and marketing of prescription and over-the-counter medicines, and healthcare products. Purdue is pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. Purdue’s mission is to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients, and caregivers.
Envigo provides essential research services, models and products for pharmaceutical, crop protection and chemical companies, as well as universities and other research organizations. Our business is founded on a dedication to customer service and the expertise and experience of our 3,800 people. Our customers can be confident that Envigo is committed to understanding their challenges; appreciating their perspectives and helping them achieve their goals. With over 50 locations worldwide we strive to help customers realize the full potential of their research and products as we work together to build a healthier and safer world.
Celonic AG is a privately owned CDMO based in Basel, Switzerland providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars, worldwide. With an unparalleled expertise and deep industry insights – honed over almost two decades of rigorous experience – Celonic goes one step beyond expectations, applying empathy, efficiency and excellence in all business aspects to help its clients attain their goals faster, more efficiently and reliably.
Celonic’s services include the development of cell lines, production processes as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances. In addition, Celonic licenses its proprietary CHOvolution™ cell line technology to clients, drug developer and service provider.